A case of acquired haemophilia A in a 70-year-old post COVID-19 vaccine
- PMID: 34708898
- PMCID: PMC8652744
- DOI: 10.1111/hae.14442
A case of acquired haemophilia A in a 70-year-old post COVID-19 vaccine
Conflict of interest statement
Craig Seaman has acted as a paid consultant for Bayer Pharmaceuticals, Genentech, HEMA Biologics, Sanofi Genzyme, Spark Therapeutics, and Takeda Pharmaceuticals. The remaining authors stated that they had no interests which might be perceived as posing a conflict or bias.
References
-
- Delgado J, Jimenez‐Yuste V, Hernandez‐Navarro F, Villar A. Acquired haemophilia: review and meta‐analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121: 21‐35. - PubMed
-
- Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008; 112: 250‐255. - PubMed
-
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020; 26 S6: 1‐158. - PubMed
-
- Kruse‐Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017; 92: 695‐705. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
